EA201591615A1 - Замещенные ксантины и способы их применения - Google Patents

Замещенные ксантины и способы их применения

Info

Publication number
EA201591615A1
EA201591615A1 EA201591615A EA201591615A EA201591615A1 EA 201591615 A1 EA201591615 A1 EA 201591615A1 EA 201591615 A EA201591615 A EA 201591615A EA 201591615 A EA201591615 A EA 201591615A EA 201591615 A1 EA201591615 A1 EA 201591615A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
xantheses
substituted
application
trpc5
Prior art date
Application number
EA201591615A
Other languages
English (en)
Other versions
EA028815B1 (ru
Inventor
Бертранд Ченард
Рэндэлл Галлащун
Original Assignee
Хайдра Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591615(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Хайдра Байосайенсиз, Инк. filed Critical Хайдра Байосайенсиз, Инк.
Publication of EA201591615A1 publication Critical patent/EA201591615A1/ru
Publication of EA028815B1 publication Critical patent/EA028815B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)

Abstract

Описаны соединения, композиции и способы для ингибирования ионного канала TRPC5 и расстройств, связанных с TRPC5.
EA201591615A 2013-03-15 2014-03-14 Замещенные ксантины и способы их применения EA028815B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789724P 2013-03-15 2013-03-15
PCT/US2014/027920 WO2014143799A2 (en) 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof

Publications (2)

Publication Number Publication Date
EA201591615A1 true EA201591615A1 (ru) 2016-05-31
EA028815B1 EA028815B1 (ru) 2018-01-31

Family

ID=50680155

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591615A EA028815B1 (ru) 2013-03-15 2014-03-14 Замещенные ксантины и способы их применения

Country Status (32)

Country Link
US (6) US9359359B2 (ru)
EP (1) EP2970303B3 (ru)
JP (1) JP6360149B2 (ru)
KR (1) KR102227629B1 (ru)
CN (2) CN105143229B (ru)
AU (1) AU2014228206C1 (ru)
CA (1) CA2899646C (ru)
CL (1) CL2015002738A1 (ru)
CY (1) CY1119042T1 (ru)
DK (1) DK2970303T6 (ru)
EA (1) EA028815B1 (ru)
ES (1) ES2636835T7 (ru)
HK (1) HK1217329A1 (ru)
HR (1) HRP20170840T4 (ru)
HU (1) HUE033528T4 (ru)
IL (1) IL240216B (ru)
LT (1) LT2970303T (ru)
MX (1) MX370372B (ru)
MY (1) MY189912A (ru)
NZ (1) NZ711718A (ru)
PE (1) PE20151779A1 (ru)
PH (1) PH12015502141B1 (ru)
PL (1) PL2970303T6 (ru)
PT (1) PT2970303T (ru)
RS (1) RS56066B2 (ru)
SG (1) SG11201506479TA (ru)
SI (1) SI2970303T1 (ru)
TW (1) TWI609867B (ru)
UA (1) UA117470C2 (ru)
UY (1) UY35488A (ru)
WO (1) WO2014143799A2 (ru)
ZA (1) ZA201505414B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
SI2970303T1 (sl) 2013-03-15 2017-08-31 Hydra Biosciences, Inc. Substituirani ksantini in njihove metode uporabe
EP3180342B1 (en) * 2014-08-11 2019-06-26 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
GB2553686B (en) 2015-03-27 2020-06-03 Latvian Inst Organic Synthesis Ethynylxanthines, preparation and use as calcium ion channel modulators
GB2553685B (en) 2015-03-27 2020-06-10 Latvian Inst Organic Synthesis Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis
GB2553684B (en) 2015-03-27 2020-06-03 Latvian Inst Organic Synthesis Ethynylxanthines, preparation and use for cancer treatment
JP6738405B2 (ja) * 2015-04-08 2020-08-12 ルイス アンド クラーク ファーマシューティカルズ、インコーポレイテッド Ａ２ｂ拮抗薬としてのキサンチン置換アルキニルカルバメート／逆カルバメート
CN107118586A (zh) * 2016-02-24 2017-09-01 中国科学技术大学 含氮杂环基取代的烯类化合物的用途
GB201702160D0 (en) * 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
WO2018157800A1 (en) * 2017-02-28 2018-09-07 National Institute Of Biological Sciences, Beijing Mlkl inhibitors
US11666577B2 (en) * 2017-02-28 2023-06-06 National Institute Of Biological Sciences, Beijing MLKL inhibitors
ES2903268T3 (es) * 2017-07-11 2022-03-31 Boehringer Ingelheim Int Derivados de xantina sustituida
US11623930B2 (en) 2018-03-05 2023-04-11 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
CA3119229A1 (en) 2018-12-12 2020-06-18 Boehringer Ingelheim International Gmbh Substituted xanthine derivatives
EP3894409B1 (en) 2018-12-12 2023-08-23 Boehringer Ingelheim International GmbH Substituted xanthine derivatives
CN112979651B (zh) * 2021-04-09 2022-02-01 南京纽邦生物科技有限公司 一种副黄嘌呤的制备方法
CN113354646B (zh) * 2021-07-06 2022-11-15 南开大学 8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用
CN115636831A (zh) * 2022-10-27 2023-01-24 中国药科大学 稠合嘧啶二酮类化合物、其用途以及药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4304650A1 (de) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JP4191269B2 (ja) 1996-05-17 2008-12-03 興和株式会社 新規なアニリド化合物及びこれを含有する医薬
JPH10318487A (ja) 1997-05-16 1998-12-04 Mitsubishi Gas Chem Co Inc 真空断熱材用ゲッタ
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
ATE312102T1 (de) * 1999-04-09 2005-12-15 Cell Therapeutics Inc Xanthinderivate und analoge als zellsignalisierung inhibitoren
CN1440288A (zh) * 2000-07-04 2003-09-03 诺沃挪第克公司 作为酶dpp－iv的抑制剂的杂环化合物
AU2002239508B9 (en) 2000-12-07 2005-09-08 Gilead Palo Alto, Inc. Substituted 1, 3, 5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis
KR100926247B1 (ko) * 2001-02-24 2009-11-12 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
RU2318824C2 (ru) * 2001-11-09 2008-03-10 Си Ви Терапьютикс, Инк. Антагонисты рецептора аденозина a2b, фармацевтическая композиция на их основе и способ их получения
AU2003249604B2 (en) * 2003-05-06 2011-06-30 Gilead Sciences, Inc. A2B adenosine receptor antagonists
AU2004291102A1 (en) 2003-11-13 2005-06-02 Board Of Regents, The University Of Texas System Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
EP1841448A2 (en) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
US8143254B2 (en) 2005-02-18 2012-03-27 Cornell Research Foundation, Inc. Methods for modulating ion channels
ATE487719T1 (de) * 2005-08-10 2010-11-15 Glaxosmithkline Llc Xanthinderivate als selektive hm74a-agonisten
ATE459620T1 (de) * 2005-09-06 2010-03-15 Glaxosmithkline Llc Benzimidazolthiophenverbindungen als plk- modulatoren
WO2007065595A2 (en) * 2005-12-07 2007-06-14 Ucb Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
CN101384261B (zh) * 2005-12-22 2011-12-07 海德拉生物科学公司 治疗疼痛的组合物
WO2007084728A2 (en) 2006-01-19 2007-07-26 Abbott Laboratories 2-imino-benzimidazoles
WO2007101213A2 (en) 2006-02-28 2007-09-07 Kalypsys, Inc. Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
US20090269313A1 (en) * 2006-07-19 2009-10-29 Diakine Therapeutics, Inc. Encapsulation system
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
US20120148604A1 (en) 2009-08-20 2012-06-14 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
WO2011114184A1 (en) * 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides of heterocyclic compounds as trpa1 inhibitors
US9260430B2 (en) 2010-06-08 2016-02-16 Hydra Biosciences, Inc. Use of TRPA1 antagonists to prevent or treat infections caused by biological-warfare agents
JP2013023102A (ja) * 2011-07-22 2013-02-04 Panasonic Corp 列車情報提供システム
WO2013023102A1 (en) * 2011-08-09 2013-02-14 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel trpa1
CN103121970B (zh) 2012-12-04 2015-04-29 中国科学院昆明植物研究所 苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用
SI2970303T1 (sl) 2013-03-15 2017-08-31 Hydra Biosciences, Inc. Substituirani ksantini in njihove metode uporabe

Also Published As

Publication number Publication date
HUE033528T2 (hu) 2017-12-28
AU2014228206B2 (en) 2018-05-10
SI2970303T1 (sl) 2017-08-31
CN107082782A (zh) 2017-08-22
PL2970303T3 (pl) 2017-08-31
UA117470C2 (uk) 2018-08-10
LT2970303T (lt) 2017-07-25
EA028815B1 (ru) 2018-01-31
PT2970303T (pt) 2017-06-23
US9359359B2 (en) 2016-06-07
IL240216B (en) 2018-11-29
EP2970303B9 (en) 2017-09-20
CL2015002738A1 (es) 2016-06-10
DK2970303T3 (en) 2017-06-26
US20170305910A1 (en) 2017-10-26
EP2970303B3 (en) 2018-08-01
US20140275071A1 (en) 2014-09-18
PH12015502141A1 (en) 2016-01-25
HRP20170840T1 (hr) 2017-09-08
KR102227629B1 (ko) 2021-03-16
JP6360149B2 (ja) 2018-07-18
TWI609867B (zh) 2018-01-01
SG11201506479TA (en) 2015-09-29
ES2636835T3 (es) 2017-10-09
PE20151779A1 (es) 2015-11-20
US20230040259A1 (en) 2023-02-09
WO2014143799A4 (en) 2015-02-12
HUE033528T4 (en) 2018-05-02
US11208409B2 (en) 2021-12-28
TW201533044A (zh) 2015-09-01
BR112015021164A2 (pt) 2017-07-18
PL2970303T6 (pl) 2018-12-31
US9969736B2 (en) 2018-05-15
US10399982B2 (en) 2019-09-03
UY35488A (es) 2014-10-31
DK2970303T5 (en) 2018-01-02
CN105143229A (zh) 2015-12-09
CN105143229B (zh) 2017-06-30
NZ711718A (en) 2020-05-29
EP2970303A2 (en) 2016-01-20
ZA201505414B (en) 2016-03-30
US20180244674A1 (en) 2018-08-30
WO2014143799A2 (en) 2014-09-18
CN107082782B (zh) 2020-03-20
ES2636835T7 (es) 2018-11-20
US20160237089A1 (en) 2016-08-18
EP2970303B1 (en) 2017-05-10
AU2014228206C1 (en) 2018-10-25
WO2014143799A9 (en) 2014-12-24
IL240216A0 (en) 2015-09-24
HK1217329A1 (zh) 2017-01-06
US11958854B2 (en) 2024-04-16
HRP20170840T4 (hr) 2018-11-16
BR112015021164A8 (pt) 2019-12-03
CY1119042T1 (el) 2018-01-10
DK2970303T6 (en) 2018-10-08
JP2016513717A (ja) 2016-05-16
MX370372B (es) 2019-12-11
MY189912A (en) 2022-03-21
PH12015502141B1 (en) 2016-01-25
WO2014143799A3 (en) 2014-11-06
AU2014228206A1 (en) 2015-09-24
US20190322667A1 (en) 2019-10-24
CA2899646A1 (en) 2014-09-18
RS56066B2 (sr) 2018-09-28
KR20150133233A (ko) 2015-11-27
CA2899646C (en) 2021-08-31
RS56066B1 (sr) 2017-10-31
MX2015011617A (es) 2016-04-25

Similar Documents

Publication Publication Date Title
EA201591615A1 (ru) Замещенные ксантины и способы их применения
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201891211A1 (ru) Ингибиторы cxcr2
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201891251A1 (ru) Бициклические ингибиторы pad4
MX2016004927A (es) Composiciones utiles para tratar trastornos relacionados con kit.
EA201591960A1 (ru) Ингибиторы акк и их применение
EA201490806A1 (ru) Комбинированный состав двух противовирусных соединений
PH12015502048A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
DK2986726T3 (da) Hidtil ukendte bacillusstammesammensætninger
MX2018001447A (es) Bloqueadores de canal de ion cargado y metodos para su uso.
EA201591962A1 (ru) Ингибиторы акк и их применение
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
DK3193880T3 (da) Hæmning af den transiente receptor-potential-A1-ionkanal

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM